Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:ZGNX

Zogenix (ZGNX) Stock Price, News & Analysis

Zogenix logo

About Zogenix Stock (NASDAQ:ZGNX)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$26.68
$26.68
50-Day Range
$26.10
$26.68
52-Week Range
$11.03
$26.90
Volume
94 shs
Average Volume
3.76 million shs
Market Capitalization
$1.50 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA.

Remove Ads
Receive ZGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zogenix and its competitors with MarketBeat's FREE daily newsletter.

ZGNX Stock News Headlines

Hwasung Industrial Co Ltd 002460
30-year market phenomenon opens up overnight opportunity
We get a chance to target these overnight returns up to FOUR times each week. Now, there would have been smaller wins and those that did not work out and I can’t promise future returns or guarantee against losses… But this is a new way for everyday folks to target a couple hundred bucks or more nearly every single day the markets are open… Regardless of which way the markets are headed… Up, down or FLAT! And now… We can target MORE payouts in LESS time! It’s a total game-changer…
Alcon (NYSE: ALC)
Longeveron Inc Ordinary Shares - Class A
Biocryst Pharmaceuticals
See More Headlines

ZGNX Stock Analysis - Frequently Asked Questions

Zogenix, Inc. (NASDAQ:ZGNX) posted its quarterly earnings results on Thursday, November, 4th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.96) by $0.08. The firm's revenue for the quarter was up 690.6% compared to the same quarter last year.

Based on aggregate information from My MarketBeat watchlists, some other companies that Zogenix investors own include Bristol-Myers Squibb (BMY), QUALCOMM (QCOM), Gilead Sciences (GILD), GW Pharmaceuticals (GWPH), Intel (INTC), Meta Platforms (META) and NVIDIA (NVDA).

Company Calendar

Last Earnings
11/04/2021
Today
3/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:ZGNX
Employees
218
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-209,380,000.00
Net Margins
-278.38%
Pretax Margin
-278.26%

Debt

Sales & Book Value

Annual Sales
$81.69 million
Price / Cash Flow
N/A
Book Value
$6.64 per share
Price / Book
4.02

Miscellaneous

Free Float
53,922,000
Market Cap
$1.50 billion
Optionable
Optionable
Beta
0.89
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:ZGNX) was last updated on 3/13/2025 by MarketBeat.com Staff
From Our Partners